Results from a recent phase 2 clinical trial of ilixadencel plus sunitinib for the treatment of newly-diagnosed metastatic renal cell carcinoma (RCC) were presented at the 2020 American Society of Clinical Oncology (ASCO)/Society for Immunotherapy of cancer (SITC) Clinical Immuno-Oncology Symposium, in Orlando, Florida, in February. Ilixadencel is an immune primer designed to increase the body’s […]
Papillary renal cell carcinoma (PRCC) is a rare subtype of renal cell carcinoma (RCC), accounting for 10%-15% of all cases of RCC. There are two types of papillary RCC; type 1 and type 2. Currently, there is an unmet need for an effective first-line treatment for metastatic PRCC. A recent phase 2 study, published in […]
A paper published in The Oncologist last month analysed real-world data to further evaluate the effectiveness of first-line sunitinib in patients with metastatic renal cell carcinoma (mRCC) with favourable, intermediate or poor risk disease according to the International mRCC Database Consortium (IMDC) risk criteria. The study included 1769 patients; 318 (18.0%) had favourable risk, 1031 […]
A recent literature review and network meta-analysis of phase 2/3 randomised, controlled clinical trials of approved first-line tyrosine kinase inhibitors (TKIs) involving more than 4,200 patients with metastatic renal cell carcinoma (RCC) has shown that cabozantinib, sunitinib, pazopanib, and tivozanib have similar efficacy, but tivozanib’s safety profile is superior to the profiles of the other […]
Approval of axitinib plus pembrolizumab and axitinib plus avelumab in the first-line treatment of metastatic renal cell carcinoma (RCC) by both the Food and Drug Administration (FDA) in America and the European Commission represent milestone events for the treatment of metastatic RCC in 2019. Approval of the avelumab plus axitinib combination was based on the […]
A retrospective study of the use of targeted therapies for advanced renal cell carcinoma (RCC) in war veterans in the USA reported poorer overall survival outcomes than those from clinical trials, as well as shorter treatment durations for first-line therapies with more frequent adverse events, dose reductions, and drug discontinuations. The study was published in […]
In this paper, three clinical trials with immunotherapy combinations for the first-line treatment of clear renal cell carcinoma (RCC) are discussed. Dr Robert Motzer from Memorial Sloan Kettering Cancer Center in New York compared the findings from the three trials at the Annual Chemotherapy Foundation Symposium (CFS) in New York last week. All three phase […]
Non-clear cell renal cell carcinoma (RCC) and sarcomatoid renal cell carcinoma are often treated similarly to clear cell RCC with the tyrosine kinase inhibitors, sunitinib and pazopanib. A recent study investigated the effectiveness of these two drugs for the first-line treatment of metastatic non-clear cell and sarcomatoid RCC. Of the 53 patients included in the […]
A recent study looked at the impact of stopping sunitinib during the first two cycles of treatment for metastatic renal cell carcinoma (RCC). Ninety-seven patients were analysed retrospectively and divided into two groups; those who had a dose interruption during the first two cycles of sunitinib treatment and those who did not. Thirty-eight patients (39.2%) […]
This interview with Dr Monty Pal, Associate Professor from the City of Hope National Medical Center in California, USA discusses tumour shrinkage in patients who did not have a nephrectomy. The interview was conducted at the European Society of Medical Oncology (ESMO) 2019 conference in Barcelona earlier this month. Dr Pal discusses the results from […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
